title: [A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group].
abstract: To determine the effect of the Chinese herbal medicine, Sairei-to (TJ-114) in children with newly diagnosed IgA nephropathy showing focal/minimal mesangial proliferation, we undertook a prospective controlled study. One hundred and one patients were randomly assigned to receive Sairei-to for 2 years (group 1) or no drug for 2 years (group 2). Forty-six of the 50 patients in group 1 and 48 of the 51 patients in group 2 completed their trial. At entry, the two groups of patients did not differ in the clinical, laboratory and pathologic findings. At the end of the trial, urinary protein excretion and hematuria were significantly reduced in group 1, but were unchanged in group 2. Twenty-one group 1 patients (46%) had normal urine, but only 5 group 2 patients (10%) had normal urine at the end of the trial (p < 0.001). Blood pressure and creatinine clearance were normal at the end of the trial in all but one group 2 patient, who developed chronic renal failure. The present study demonstrates that 2-year Sairei-to treatment early in the course of disease is effective in children with IgA nephropathy showing focal/minimal mesangial proliferation.
authors.affiliation: Faculty of Health Science, Kobe University School of Medicine.
authors.forename: N
authors.initials: N
authors.lastname: Yoshikawa
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: Y
authors.initials: Y
authors.lastname: Takekoshi
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: M
authors.initials: M
authors.lastname: Awazu
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Iitaka
authors.forename: Y
authors.initials: Y
authors.lastname: Koitabashi
authors.forename: K
authors.initials: K
authors.lastname: Yamaoka
authors.forename: K
authors.initials: K
authors.lastname: Nakagawa
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
authors.forename: S
authors.initials: S
authors.lastname: Matsuyama
authors.forename: Y
authors.initials: Y
authors.lastname: Seino
authors.forename: N
authors.initials: N
authors.lastname: Takeda
authors.forename: S
authors.initials: S
authors.lastname: Hattori
authors.forename: M
authors.initials: M
authors.lastname: Ninomiya
mesh_terms: D000293:Adolescent; D002648:Child; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000188:drug therapy*; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy; D006801:Humans; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D004365:Drugs, Chinese Herbal